Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Hemington Wealth Management

Hemington Wealth Management grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 437 shares of the medical research company’s stock after acquiring an additional 25 shares during the quarter. Hemington Wealth Management’s holdings in Thermo Fisher Scientific were worth $255,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. WCM Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after purchasing an additional 2,928 shares during the period. Summa Corp. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $418,000. Phoenix Holdings Ltd. grew its holdings in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares during the period. S. R. Schill & Associates grew its holdings in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after purchasing an additional 792 shares during the period. Finally, Tsfg LLC boosted its holdings in Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after acquiring an additional 19 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock worth $12,532,780 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMO. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft raised their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. HSBC raised their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Finally, The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $606.47.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $5.67 during trading hours on Thursday, hitting $542.54. The stock had a trading volume of 1,402,436 shares, compared to its average volume of 1,541,105. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a market capitalization of $207.10 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 2.50 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock’s fifty day moving average is $569.33 and its two-hundred day moving average is $563.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.